Latest American Mental and Medical Health News Thread, Otsuka Pharmaceutical Co., Ltd. Announces Results From A Phase 2 Study Of Investigational Product OPC-34712 As Adjunctive Therapy In Adults With MDD in Informational; Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced results from a Phase 2 ...
-
May 16th, 2011, 8:15 AM
#1
Otsuka Pharmaceutical Co., Ltd. Announces Results From A Phase 2 Study Of Investigational Product OPC-34712 As Adjunctive Therapy In Adults With MDD
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced results from a Phase 2 clinical trial of OPC-34712, a novel D2 dopamine partial agonist investigational product. In a six-week, double-blind, randomized, placebo-controlled study, OPC-34712 (1.5 ± 0...
More...
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
LinkBack URL
About LinkBacks
Reply With Quote